First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis.

Creator(s)

Sanet Torres-Torres, Children's Mercy Hospital
Angela Myers, Children's Mercy HospitalFollow
J Michael Klatte, Children's Mercy Hospital
Eric E Rhoden
M Steven Oberste
Marc S. Collett
Russell J. McCulloh, Children's Mercy Hospital

Document Type

Article

Publication Date

1-2015

Identifier

DOI: 10.1097/INF.0000000000000497

Abstract

Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

Journal Title

The Pediatric infectious disease journal

Volume

34

Issue

1

First Page

52

Last Page

54

MeSH Keywords

Antiviral Agents; Enterovirus B, Human; Enterovirus Infections; Female; Humans; Infant, Newborn; Poliovirus; Sepsis; Treatment Outcome

Keywords

Antiviral Agents; Enterovirus B, Human; Enterovirus Infections; Female; Humans; Infant, Newborn; Poliovirus; Sepsis; Treatment Outcome

Recommended Citation

Torres-Torres, S., Myers, A., Klatte, J., Rhoden, E., Oberste, M. S., Collett, M. S., McCulloh, R. J. First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis. The Pediatric infectious disease journal 34, 52-54 (2015).